TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03139760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWERSforID
Description: Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
Study: NCT00694616

Intervention type: DEVICE
Group type: OTHER
Intervention: AutoSet Spirit
Description: 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between

Intervention type: DEVICE
Group type: OTHER
Intervention: Modified-AutoSet Spirit
Description: 3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
Study: NCT02949609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
Study: NCT03798106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, pazopanib
Description: Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
Study: NCT00549692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethylester90
Description: Dosage form :1g soft capsule Dosage : two capsules, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acid ethylester90
Description: Dosage form :1g soft capsule Dosage : two capsules, twice a day.
Study: NCT04363203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo in pill packs identical to study drugs
Study: NCT01636765

Intervention type: DRUG
Intervention: No Intervention
Description: No intervention.
Study: NCT01361555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-820836
Description: Tablet, Oral, 0.0 mg, Once daily, 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-820836
Description: Tablet, Oral, 0.0 mg, Once daily, 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-820836
Description: Tablet, Oral, 0.0 mg, Once daily, 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.5 mg, Once daily, 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 1.0 mg, Once daily, 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 2.0 mg, Once daily, 54 weeks
Study: NCT01792700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tripotassium dicitrate bismuthate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Study: NCT00317473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A Malaria vaccine
Description: Subjects vaccinated with FMP1/AS02 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A Malaria vaccine
Description: Subjects vaccinated with FMP1/AS02 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A Malaria vaccine
Description: Subjects vaccinated with FMP1/AS02 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax Rabies vaccine
Description: Subjects vaccinated on corresponding FMP1/AS02A vaccination days
Study: NCT05772741

Intervention type: OTHER
Group type: OTHER
Intervention: Biological sample collection
Description: Collection of biological samples
Study: NCT04265196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral group therapy
Description: A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Description: Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
Study: NCT01590264

Intervention type: DEVICE
Group type: OTHER
Intervention: Bimodal rTMS
Description: High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000
Study: NCT01329978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
Study: NCT03524053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise induced bronchoconstriction
Description: Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
Study: NCT01329978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT01233596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canalicular intubation
Description: Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canalicular intubation
Description: Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
Study: NCT01204099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Study: NCT01031719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted A(H1N1) influenza vaccine
Description: 7.5 ug of HA antigen; adjuvanted; monovalent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted A(H1N1) influenza vaccine
Description: 7.5 ug of HA antigen; adjuvanted; monovalent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-adjuvanted A(H1N1) influenza vaccine
Description: 15ug of HA antigen, non-adjuvanted; trivalent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: non-adjuvanted A(H1N1) influenza vaccine
Description: 15 mcg of antigen; non-adjuvanted; trivalent
Study: NCT01222845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
Study: NCT03400618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Description: 30 E % carbohydrates included in the diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate diet
Description: 50 E % carbohydrates included in the diet
Study: NCT02922530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-based Adaptive Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study: NCT03557970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edicotinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT04562922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lifemel
Study: NCT00701285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: pitavastatin 4mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: pravastatin 10mg once daily
Study: NCT03524053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhibited EIB
Description: Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
Study: NCT02723331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Study: NCT01477554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRONTO training
Description: PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
Study: NCT02641860

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal progenitor cells
Description: Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal progenitor cells
Description: Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal progenitor cells
Description: Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
Study: NCT00875927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no scraping microcapsules
Description: 1, 4 grams isomalt candy containing no scraping microcapsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing inert TCP microcapsules
Description: 1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing Propolis
Description: 1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing and Zinc
Description: 1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scraping microcapsules containing Propolis and Zinc
Description: 1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
Study: NCT01058031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness Based Stress Reduction
Study: NCT00860730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement with Perceval aortic heart valve
Description: Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
Study: NCT00724841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax Mesylate
Description: Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT04050046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based cognitive therapy (CBCT)
Description: Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer-based cognitive therapy (CBCT)
Description: Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
Study: NCT02893709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
Study: NCT03494270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe
Description: Rosuvastatin 10mg/Ezetimibe 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova
Description: Rosuvastatin 20mg
Study: NCT01766453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: Aerobic exercise with a progressive increase in intensity over 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bhangra dance exercise
Description: Bhangra Dance classes taught by an instructor.
Study: NCT00828971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicilline/clavulanic
Description: IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
Study: NCT02579200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POWERbreathe®KHA (IMT group)
Description: 2 training sessions/day consisting of 30 breaths (\~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual \~50% Pimax values.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: POWERbreathe®KH2 (sham group)
Description: 2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
Study: NCT03324490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Spinal Anesthesia
Description: Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) \& 5 μg dexmedetomidine will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Anesthesia
Description: Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle \& a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose \& continued throughout the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% (hyperbaric)
Description: Neuro-axially injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5% (isobaric)
Description: Neuro-axially injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Neuro-axially injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Neuro-axially injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Neuro-axially injected